Novo Nordisk A/S (NVO) has a consensus analyst rating of Buy, based on 39 analysts covering the stock. Of those, 23 recommend buying, 13 recommend holding, and 3 recommend selling.
The analyst consensus price target for NVO is $47.00, representing a +19.5% upside from the current price of $39.32. Price targets range from a low of $42.00 to a high of $54.00.
